NOTV vs. PMVP, LUNA, ONMD, BIAF, DKDCA, AIKI, ISPC, FOXO, PGEN, and OCGN
Should you be buying Inotiv stock or one of its competitors? The main competitors of Inotiv include PMV Pharmaceuticals (PMVP), Luna Innovations (LUNA), OneMedNet (ONMD), bioAffinity Technologies (BIAF), Data Knights Acquisition (DKDCA), AIkido Pharma (AIKI), iSpecimen (ISPC), FOXO Technologies (FOXO), Precigen (PGEN), and Ocugen (OCGN).
Inotiv (NASDAQ:NOTV) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, community ranking, media sentiment, profitability, dividends, risk and institutional ownership.
In the previous week, PMV Pharmaceuticals had 4 more articles in the media than Inotiv. MarketBeat recorded 5 mentions for PMV Pharmaceuticals and 1 mentions for Inotiv. Inotiv's average media sentiment score of 0.94 beat PMV Pharmaceuticals' score of 0.72 indicating that Inotiv is being referred to more favorably in the media.
Inotiv has a beta of 3.37, meaning that its share price is 237% more volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.
PMV Pharmaceuticals has a net margin of 0.00% compared to Inotiv's net margin of -12.90%. Inotiv's return on equity of -11.23% beat PMV Pharmaceuticals' return on equity.
PMV Pharmaceuticals received 3 more outperform votes than Inotiv when rated by MarketBeat users. Likewise, 60.00% of users gave PMV Pharmaceuticals an outperform vote while only 47.37% of users gave Inotiv an outperform vote.
Inotiv presently has a consensus target price of $6.19, suggesting a potential upside of 230.88%. PMV Pharmaceuticals has a consensus target price of $5.75, suggesting a potential upside of 215.93%. Given Inotiv's higher possible upside, equities research analysts plainly believe Inotiv is more favorable than PMV Pharmaceuticals.
18.2% of Inotiv shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 5.8% of Inotiv shares are held by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
PMV Pharmaceuticals has lower revenue, but higher earnings than Inotiv. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Inotiv, indicating that it is currently the more affordable of the two stocks.
Summary
PMV Pharmaceuticals beats Inotiv on 11 of the 18 factors compared between the two stocks.
Get Inotiv News Delivered to You Automatically
Sign up to receive the latest news and ratings for NOTV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NOTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
